Details for New Drug Application (NDA): 218347
✉ Email this page to a colleague
NDA 218347 describes RINVOQ LQ, which is a drug marketed by Abbvie and is included in one NDA. It is available from one supplier. Additional details are available on the RINVOQ LQ profile page.
The generic ingredient in RINVOQ LQ is upadacitinib. One supplier is listed for this compound. Additional details are available on the upadacitinib profile page.
The generic ingredient in RINVOQ LQ is upadacitinib. One supplier is listed for this compound. Additional details are available on the upadacitinib profile page.
Summary for 218347
| Tradename: | RINVOQ LQ |
| Applicant: | Abbvie |
| Ingredient: | upadacitinib |
| Patents: | 0 |
Pharmacology for NDA: 218347
| Mechanism of Action | Janus Kinase Inhibitors |
Suppliers and Packaging for NDA: 218347
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| RINVOQ LQ | upadacitinib | SOLUTION;ORAL | 218347 | NDA | AbbVie Inc. | 0074-2320 | 0074-2320-01 | 1 BOTTLE in 1 CARTON (0074-2320-01) / 180 mL in 1 BOTTLE |
| RINVOQ LQ | upadacitinib | SOLUTION;ORAL | 218347 | NDA | AbbVie Inc. | 0074-2320 | 0074-2320-70 | 1 BOTTLE in 1 CARTON (0074-2320-70) / 180 mL in 1 BOTTLE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;ORAL | Strength | 1MG/ML | ||||
| Approval Date: | Apr 26, 2024 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
